vTv Therapeutics appoints Dr. Jonathan Isaacsohn as Chair of the Board

vTv Therapeutics Inc.

Dr. Jonathan Isaacsohn appointed as member and Chair of Board effective August 9, 2022.
He is President and CEO of CinRx Pharma, LLC; appointment per July 22, 2022 stock purchase agreement.
Annual cash compensation of $70,000 plus annual equity grant of 50,000 options; initial grant of 50,000 options on appointment.
Dr. Isaacsohn has over 25 years in drug development; served as CMO of Teva Pharmaceutical Industries.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jonathan Isaacsohn

Chair of the Board

VTVT · vTv Therapeutics Inc.

Effective: 2022-08-09
Filed: August 15, 2022, 7:59 PM ET

appointed Dr. Jonathan Isaacsohn as a member and chair of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jonathan Isaacsohn was appointed as Chair of the Board at vTv Therapeutics Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

appointed Dr. Jonathan Isaacsohn as a member and chair of the Board, effective immediately.

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-002532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.